EL7.AI
StocksMedium•16 November 2026•
2 min read

Zymeworks buys back $115.6 million in shares under 2026 program

Key Facts

1Zymeworks’ purchases under its 2026 program totaled about $115.6 million through November 6.
2The average purchase price was $26.63 a share through November 6.
3$9.4 million of capacity remained under the share repurchase program as of November 6.
4The company estimated that its cash resources would cover operating expenses and capital expenditures for at least 12 months from the date the report was filed.

Zymeworks had repurchased $115.6 million of shares through November 6, 2026, under its 2026 program, authorized by the board in May with a cap of $125 million. The company said in its quarterly report that it bought the shares at an average price of $26.63 a share. EL7 data showed the stock closed at $26.24 on November 13. It had closed at $30.81 on November 9. That places the program’s purchases and the share price in the context of its moves in the days before the latest closing date in the data.

The company said it had $9.4 million of remaining capacity in the program as of November 6. It also said it had repurchased 4,340,965 shares through that date. The authorization allows share purchases in the open market or by other means under Rules 10b5-1 and 10b-18 of the Exchange Act. The company said the program “may be suspended or discontinued at any time and does not obligate us to purchase additional shares.” Purchases therefore remain at the company’s discretion, and the authorization cap does not mean it will use the full amount.

On its cash resources, Zymeworks said cash and cash equivalents, including a $250 million milestone payment from Jazz received in October 2026, were sufficient to cover operating expenses and capital expenditures for at least 12 months from the date the report was filed. The company’s estimate excluded potential future milestone payments from partners, noting that they remain subject to conditions. The company completed its acquisition of Theravance Biopharma on September 23. It said the acquisition added recurring commercial cash flow through the drug YUPELRI. It also linked the Jazz payment to U.S. Food and Drug Administration approval of Ziihera for first-line treatment of advanced HER2-positive gastric and gastroesophageal junction adenocarcinoma.

In a separate collaboration with Roche, the company said the partnership provides a path to develop ZW209 while preserving long-term economic participation. Completion of the waiting period under competition law was expected during the fourth quarter of 2026. On its results, Zymeworks said it would not hold a conference call after publishing its third-quarter results. These developments link the buyback program to a period that includes the acquisition, expanded revenue sources and research collaboration. The liquidity estimate published in the report continues to exclude conditional future partner payments.

Open on chart